French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-99
SponsorThe Lymphoma Academic Research Organisation

About this trial

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center

If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive

Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.

Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019

Disqualifiers

None

Trial population

Patient eligible for a treatment with CAR-T for an hematological malignancy

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

overall survival from eligibility

Time frame
15 years
2

Overall survival from administration

Time frame
15 years
3

complete response rate

Time frame
15 years
4

Progression free survival

Time frame
15 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Lymphoma Academic Research Organisation

Lead sponsor

Gilead Sciences

Collaborator

Novartis

Collaborator

Bristol-Myers Squibb

Collaborator